Daily Newsletter

16 February 2024

Daily Newsletter

16 February 2024

Johnson & Johnson unveils presbyopia-correcting IOL in EMEA

The TECNIS PureSee IOL is intended to offer high contrast and low-light performance on par with a monofocal intraocular lens (IOL).

Archana Rani February 16 2024

Johnson & Johnson MedTech has announced the availability of its TECNIS PureSee IOL in the Europe, the Middle East and Africa (EMEA) region.

This next-generation lens is designed to correct presbyopia with a purely refractive design, aiming to provide patients with high-quality, uninterrupted vision.

The TECNIS PureSee IOL is intended to offer high contrast and low-light performance on par with a monofocal IOL.

It addresses the common trade-offs faced by surgeons and patients such as the choice between clear vision at all distances and the potential for visual disturbances like glares and halos.

The refractive design of the IOL is crafted to facilitate surgeons' work by providing high tolerance to refractive error.

The lens has several benefits, including uninterrupted high-quality vision across distances, functional near vision for reduced dependence on glasses, and a dysphotopsia profile that minimises visual symptoms.

Johnson & Johnson EMEA vision president Jacqueline Henderson said: “Cataract surgery is the number one surgery performed globally, with 28 million procedures each year. But only 10%-15% of patients are getting advanced optical IOLs specifically designed for astigmatism and presbyopia.

“Today, we’re proud to launch the TECNIS PureSee IOL, giving surgeons and patients the choice of a premium IOL that combines clarity of vision and reduced visual symptoms.”

Cataracts remain the leading cause of treatable blindness globally, the company said.

Currently, the TECNIS PureSee IOL is accessible in select markets within the EMEA region.

Advalia Vision, Milano, Italy medical director & physician CEO Dr Francesco Carones said: “I’ve found that this new refractive PC-IOL reliably delivers consistent, uninterrupted, high-quality vision with excellent distance vision and high contrast not only in daylight but also at night.

“Together with the low level of dysphotopsia, that is comparable to a monofocal IOL, these are exactly the results my patients are looking for.”

Last year, Johnson & Johnson MedTech acquired privately held company Laminar, a US-based developer of a heart implant that reduces the chance of stroke.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.